Meridian Bioscience (VIVO) Tops Q2 EPS by 3c

Meridian Bioscience (NASDAQ: VIVO) reported Q2 EPS of $0.19, $0.03 better than the analyst estimate of $0.16. Revenue for the quarter came in at $50.2 million versus the consensus estimate of $51.74 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.

You May Also Be Interested In

• Goldman's Garrett sees investors dialing back tech exposure into H2
• Blue Owl keeps 5% redemption caps as OCIC requests ease from prior quarter
• Prabhudas Lilladher Starts Blue Star Limited (BLSTR:IN) at Buy (1)